Health-Related Quality of Life in Patients With Metastatic Urothelial Cancer: Results of a Cross-Sectional Survey in Europe
Author(s)
Mia Unsworth, BSc Hons1, Cameron Forshaw, MS1, Maria Walley, MS1, Hannah Wear, BS1, Amber Simpson, BS1, Mairead Kearney, MB, BCh, MPH, MBA, MSC Econ2.
1Adelphi Real World, Bollington, United Kingdom, 2Global Value Demonstration, Market Access and Pricing, Biopharma, Global Operations, Merck Healthcare KGaA, Darmstadt, Germany.
1Adelphi Real World, Bollington, United Kingdom, 2Global Value Demonstration, Market Access and Pricing, Biopharma, Global Operations, Merck Healthcare KGaA, Darmstadt, Germany.
OBJECTIVES: With recent treatment approvals for patients with metastatic urothelial cancer (mUC), it is important to understand the disease burden and impact of treatment on quality of life (QoL). We aimed to address the scarcity of QoL data by describing disease burden in a real-world mUC cohort.
METHODS: Data were drawn from the Adelphi Real World mUC Disease Specific Programme™, a cross-sectional survey of medical oncologists/urologists and their patients with mUC in France, Germany, Italy, Spain, and the United Kingdom from December 2023-July 2024. Physicians reported patient demographics. Patients voluntarily completed the EQ-5D-5L (German tariff), European Organisation for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC QLQ-C30) and the Brief Pain Inventory (BPI). EQ-5D-5L scores range from one (full health) to below zero (worse than death). EORTC QLQ-C30 global health status/quality of life (GHS/QoL), function, and symptom scale scores were reported. Scores range from 0-100, where high scores indicate high function/symptomology. BPI composite and pain interference scores range from 0 (no pain/interference) to 10 (severe). Analyses were descriptive.
RESULTS: Overall, 98 physicians reported on 445 patients who provided QoL data. Mean (standard deviation; SD) patient age was 68.6 (7.8) years, 64% were male, 72% retired, and 61% had a caregiver. At survey, 20% were receiving second-line or later treatment. Mean (SD) EQ-5D-5L score was 0.77 (0.21) and EORTC QLQ-C30 GHS/QoL score was 54.1 (18.1). A mean (SD) EORTC QLQ-C30 role functioning score and fatigue score of 57.4 (28.1) and 42.6 (24.1), respectively, were reported. Mean (SD) BPI composite and interference scores were 3.3 (2.0) and 3.7 (2.2), respectively.
CONCLUSIONS: An impact on general QoL and functioning was reported despite low pain interference and symptom scale scores. This indicates a need to account for patient QoL when managing mUC, with further research into the impact of treatments on QoL needed.
METHODS: Data were drawn from the Adelphi Real World mUC Disease Specific Programme™, a cross-sectional survey of medical oncologists/urologists and their patients with mUC in France, Germany, Italy, Spain, and the United Kingdom from December 2023-July 2024. Physicians reported patient demographics. Patients voluntarily completed the EQ-5D-5L (German tariff), European Organisation for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC QLQ-C30) and the Brief Pain Inventory (BPI). EQ-5D-5L scores range from one (full health) to below zero (worse than death). EORTC QLQ-C30 global health status/quality of life (GHS/QoL), function, and symptom scale scores were reported. Scores range from 0-100, where high scores indicate high function/symptomology. BPI composite and pain interference scores range from 0 (no pain/interference) to 10 (severe). Analyses were descriptive.
RESULTS: Overall, 98 physicians reported on 445 patients who provided QoL data. Mean (standard deviation; SD) patient age was 68.6 (7.8) years, 64% were male, 72% retired, and 61% had a caregiver. At survey, 20% were receiving second-line or later treatment. Mean (SD) EQ-5D-5L score was 0.77 (0.21) and EORTC QLQ-C30 GHS/QoL score was 54.1 (18.1). A mean (SD) EORTC QLQ-C30 role functioning score and fatigue score of 57.4 (28.1) and 42.6 (24.1), respectively, were reported. Mean (SD) BPI composite and interference scores were 3.3 (2.0) and 3.7 (2.2), respectively.
CONCLUSIONS: An impact on general QoL and functioning was reported despite low pain interference and symptom scale scores. This indicates a need to account for patient QoL when managing mUC, with further research into the impact of treatments on QoL needed.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
PCR118
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Oncology